<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04628663</url>
  </required_header>
  <id_info>
    <org_study_id>DEXIOPSPS</org_study_id>
    <nct_id>NCT04628663</nct_id>
  </id_info>
  <brief_title>Effects of Dexmedetomidine on Intraocular Pressure During Scheduled Spine Surgeries</brief_title>
  <official_title>Effects of Systemic Administration of Dexmedetomidine on Intraocular Pressure During Scheduled Spine Surgeries in a Prone Position. Prospective, Randomized, Double-blinded Study.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Attikon Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Attikon Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to examine the effects of intraoperative systemic use of&#xD;
      dexmedetomidine on the intraocular pressure (IOP) in patients undergoing spine surgeries in a&#xD;
      prone position under general anesthesia.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study is a Prospective, Randomized, Placebo -controlled, Double-Blinded clinical trial&#xD;
      Adult patients with an ASA physical status of class I, II or III who are scheduled for an&#xD;
      elective spine surgery in prone position under general anesthesia will be included in the&#xD;
      study.&#xD;
&#xD;
      The patients will be randomized with closed envelope manner into two groups: the group of&#xD;
      dexmedetomidine and the group of normal saline.&#xD;
&#xD;
      In the dexmedetomidine group (DEX group), bolus dose 1,0 μg/kg of dexmedetomidine will be&#xD;
      administered in 10min before induction to anesthesia and 0,4-0,8 μg/kg/h of dexmedetomidine&#xD;
      will be infused continuously until the end of the surgery.&#xD;
&#xD;
      In the saline group (placebo group), the same volume of saline will be administered in an&#xD;
      identical way.&#xD;
&#xD;
      All study medication will be prepared by an independent anesthesiologist who is not&#xD;
      associated in the study (who will hold the randomization codes until the end of the study).&#xD;
&#xD;
      All patients will receive the same type of anaesthesia (TIVA with propofol) and postoperative&#xD;
      analgesia including paracetamol 1gr iv (4 times/day) and continuous wound infiltration with&#xD;
      ropivacaine 0.2% 5ml/h for 48 postoperative hours.&#xD;
&#xD;
      Basic monitoring for the study includes:&#xD;
&#xD;
      ECG, Invasive and noninvasive blood pressure, Heart Rate, EtCO2, SpO2, Cardiac Output (CO),&#xD;
      Stroke Volume (SV), Stroke Volume Variation (SVV), Patient State index (PSi), IOP, Urine&#xD;
      output.&#xD;
&#xD;
      Measurements&#xD;
&#xD;
      The measurement of IOP will be conducted in both eyes with Icare PRO tonometer by an&#xD;
      ophthalmologist who will not know in which group the patient is in the below predefined time&#xD;
      points:&#xD;
&#xD;
        -  T1: before administration of the study drug&#xD;
&#xD;
        -  T2: after administration of the bolus dose of the study drug&#xD;
&#xD;
        -  T3: after tracheal intubation&#xD;
&#xD;
        -  T4: just before prone position&#xD;
&#xD;
        -  T5: just after prone position&#xD;
&#xD;
        -  T6: 30min after T5&#xD;
&#xD;
        -  T7: 60min after T6&#xD;
&#xD;
        -  T8: 120min after T7&#xD;
&#xD;
        -  T9: 180min after T8&#xD;
&#xD;
        -  T10: at the end of the surgery and the patient in supine position At the time of each&#xD;
           tonometer reading the following data set is collected: MAP, heart rate, EtCO2, SpO2, CO,&#xD;
           SV, SVV, urine output, Psi, IOP. Moreover OPP will be calculated as MAP minus IOP.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">January 20, 2021</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Anticipated">July 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Prospective, Randomized, Placebo -controlled, Double-Blinded clinical trial</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
    <masking_description>Not aware of the study group</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Intraocular pressure (IOP)</measure>
    <time_frame>Up to 15 minutes after the end of operation</time_frame>
    <description>The measurement of IOP will be conducted in both eyes with Icare PRO tonometer by an ophthalmologist at predefined time points</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Intraocular Pressure</condition>
  <arm_group>
    <arm_group_label>DEX group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Dexmedetomidine given at a bolus dose of 1,0 μg/kg 10min before induction of anesthesia and then after as a continuous infusion 0,4-0,8 μg/kg/h until the end of the surgery.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Normal saline given as a bolus dose 10min before induction of anesthesia and then after as a continuous infusion until the end of the surgery.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexmedetomidine</intervention_name>
    <description>Administration</description>
    <arm_group_label>DEX group</arm_group_label>
    <other_name>Dexmed</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Normal Saline</intervention_name>
    <description>Administration</description>
    <arm_group_label>Placebo group</arm_group_label>
    <other_name>Saline</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Adult patients undergoing scheduled spine surgery performed in prone position under&#xD;
             general anaesthesia&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients who refuse to be a part of the study&#xD;
&#xD;
          -  Patients with previous eye surgery&#xD;
&#xD;
          -  Preexisting eye disease (e.g glaucoma)&#xD;
&#xD;
          -  Allergy to the study drug or any drug which is in the trial&#xD;
&#xD;
          -  Preoperative unstable hemodynamics&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Paraskevi Matsota, Prof</last_name>
    <role>Study Chair</role>
    <affiliation>2nd Department of Anesthesiology, Attikon University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Paraskevi Matsota, Prof</last_name>
    <phone>6945544563</phone>
    <email>matsota@yahoo.gr</email>
  </overall_contact>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>November 5, 2020</study_first_submitted>
  <study_first_submitted_qc>November 9, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 13, 2020</study_first_posted>
  <last_update_submitted>January 12, 2021</last_update_submitted>
  <last_update_submitted_qc>January 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 13, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Attikon Hospital</investigator_affiliation>
    <investigator_full_name>Paraskevi Matsota</investigator_full_name>
    <investigator_title>Prof of Anaesthesiology</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexmedetomidine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

